As many companies in France and in the world, the COVID-19 pandemic deeply affects our activities. For safety reasons, most of our work is now done remotely but we maintain essential activity in laboratories to take care of our cells and try to finish our ongoing customer studies. The situation Read more…
Last week, our study director Elodie was in Rennes to participate in NutrEvent! We had a booth there, under NSL Clubster pavilion (Lille Northern France Health and Nutrition clubster). It was a pleasure for her to present our activities in imaging and our 3D cell culture products to the visitors! Read more…
BIOMIMESYS® Oncology is mostly composed of hyaluronic acid (HA), biofunctionnalized with undenaturated collagen I. HA, by interacting with its binding proteins (CD44, RHAMM, ICAM-1), is an active participant in inflammatory, angiogenic, fibrotic and cancer-promoting processes (Figure 1). We are currently looking at the effect of different elastic moduli of BIOMIMESYS® Read more…
Originally, cosmetics were tested on animals, but since a couple of year’s manufacturer have tried to avoid this test to match the new regulation on animal testing. Today, most of the test will be conducted on human skin or eye tissue or even human skin culture. In order to find Read more…
Veronique obtained an engineering degree from the Toulouse agronomic school (ENSAT) in 2017, with a specialization in biotechnology at AgroParisTech. During her studies, she worked on the cholinergic receptors structure of the parasitic nematode Trichinella spiralis during a 3-month internship in the French Agency for Food, Environmental and Occupational Health Read more…
For ethical and cost-related reasons, use of animals for the assessment of mode of action, metabolism and/or toxicity of new drug candidates has been increasingly scrutinized in research and industrial applications. Physiologically based pharmacokinetic (PBPK2) modeling is the most potent in silico tool used for extrapolation of pharmacokinetic parameters to Read more…
Cell biology is part of the R&D activity in dermocosmetology, as providers of active extracts or pure compounds have to demonstrate their efficacy and safety. At HCS Pharma, we are developing new dermocosmetology assays on relevant cellular models, like human primary keratinocytes and human primary fibroblasts, using our automated platform and high content analysis system.
A very interesting talk will be done by Marc Pissavini in next Cosmeticdays (1st and 2nd December in Marseille).
ESTIV conference, named In Vitro Toxicology for Human Safety Assessment, takes place this week in Juan-les-Pins. This congress brings together a lot of toxicologists, from public and private, to discuss the last development of predictive in vitro models in safety testing, as 3D models, organ-on-a-chip, bioprint organs. To learn more and to exchange on these Read more…